15817-85-3

Usage

Physical state

Yellow liquid

Odor

Sweet

Industry use

Fragrance and flavor industry

Synthesis use

Precursor in the synthesis of various pharmaceuticals and agrochemicals

Researched for

Potential therapeutic effects in the treatment of neurological and psychiatric disorders

Psychoactive effects

Yes, may pose health risks when misused as a recreational drug

Regulation

Production, distribution, and use are regulated in many countries

Upstream product

• 36724-24-0 3-ethylbenzo[b]furan 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 19728-14-4 2-(2-propanoylphenoxy)acetic acid 
• 100612-85-9 ethyl 2-(2-propanoylphenoxy)acetate 
• 610-99-1 1-(2-Hydroxy-phenyl)-propan-1-on 
• 78-95-5 chloroacetone 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME

In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed.

Enantioseparation of propafenone-type modulators of multidrug resistnace on cyclodextrin based chiral stationary phases

Enantioseparation of propafenone-type MDR-modulators on a rac-hydroxypropyl modified β-cyclodextrin CSP (CYCLOBOND I RSP) and a (S)-naphthylethylcarbamate modified column (CYCLOBOND I SN) is investigated. Best result could be achieved using the multimodal CYCLOBOND I SN column in the polar organic mode. Generally, the conformationally restricted benzofuranylethanolamines 2a and 2b showed remarkable higher α values than the corresponding propafenone derivatives 1a-e.

Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance

A series of benzofurylethanolamine analogs of propafenone (1a) have been prepared and evaluated for multidrug resistance-reversing activity in two in vitro assay systems. As for propafenones, an excellent correlation of biological data with calculated lipophilicity values was found for benzofurans, whereby the latter generally had lower activity/lipophilicity ratios. Almost identical slopes of the regression lines were obtained for both propafenones and benzofurans. Multiple linear regression analysis of the complete data set yielded an equation with excellent predictive power (r2(cross-valid) = 0.968). Interaction measurements with artificial membranes indicated that the differences in activity between these two series of compounds are not due to differences in the interaction pattern with biological membranes.